3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
8
Venous Thromboembolism
4
Polycythemia Vera
3
Prostatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Breast Neoplasms
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Smoking Cessation
1
Sarcoma
1
Primary Myelofibrosis
1
Ovarian Neoplasms
1
Ovarian Cancer Prevention
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Liver Cirrhosis
1
Leukemia, Hairy Cell
1
Inflammation
1
Hemorrhage
1
Hematoma
1
Fibrosis
1
Endometrial Neoplasms
1
Colorectal Neoplasia
1
Interventions
pembrolizumab
25
Cisplatin
23
Carboplatin
18
Magnetic Resonance Spectroscopy
16
Paclitaxel
15
Specimen Handling
14
Pemetrexed
11
durvalumab
9
Radiotherapy, Intensity-Modulated
8
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Nivolumab
7
Radiation
6
Docetaxel
6
Cetuximab
6
Biopsy
6
osimertinib
5
cemiplimab
5
Taxes
5
Radiotherapy
5
Ipilimumab
5
Cyclophosphamide
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
poly ICLC
4
cabozantinib
4
atezolizumab
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Aspirin
×
1 year
×
Clear all
NCT07529262
2026-04-14
AspiRe HCC
Curtin University
Phase 3
Not yet recruiting
890 enrolled